Glen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glen

Property Description
Active Ingredient Ceftriaxone
Form Sterile powder for solution
Pharmacological Class Third-generation cephalosporin antibiotic
General Purpose Treatment and prevention of bacterial infections
Origin Semisynthetic

What Type of Antibiotic is Glen (Ceftriaxone)?

Glen is a specific trade name for a potent, prescription-only (Rx-only) medication whose active ingredient is Ceftriaxone. It is classified as a semisynthetic third-generation cephalosporin antibiotic, a critical agent within the larger beta-lactam family of antibacterials. As a broad-spectrum, third-generation cephalosporin, Ceftriaxone represents an advanced classification among antibacterial drugs. This formulation is characterized as a single-active ingredient product. The semisynthetic origin means the compound is manufactured in a laboratory, enhancing its therapeutic properties and providing the necessary broad-spectrum coverage against many susceptible bacteria.


How Does This Medicine Generally Work and What is its Purpose?

The general purpose of Glen (Ceftriaxone) is to treat or prevent a wide range of clinically relevant bacterial infections. Its fundamental mode of action is bactericidal, meaning it actively kills the infectious organisms rather than just inhibiting their growth. The medication is utilized for its recognized high value for public health and reliable efficacy against various pathogens. This selective destruction is achieved through the disruption of the vital bacterial cell wall synthesis, a process essential for the structural integrity and survival of the bacteria. For the patient, this mechanism ensures a direct and decisive approach to eliminating the cause of the bacterial pathology.


What is the Physical Form of Glen?

The medication is supplied as a sterile, white to yellowish-orange powder for solution, which must be reconstituted with a sterile aqueous diluent before use. It is administered exclusively by the parenteral route, which means the final liquid solution is given via intravenous (IV) injection or infusion, or as an intramuscular (IM) injection. This requirement for professional delivery via injection is critical, as the active ingredient is not adequately absorbed when taken orally, ensuring the entire dose reaches the bloodstream to achieve the necessary systemic therapeutic effect for treating infections throughout the body. The typical presentation is in vials designed for single-use parenteral administration.

What side effects are possible with Glen?

Possible Side Effects and Safety Information

Glen (Ceftriaxone) is associated with an official safety profile that classifies potential adverse effects by frequency and the body system affected, based on authoritative regulatory documentation.

Adverse Reaction Classifications

The most Common adverse reactions, defined as occurring in 1% to 10% of patients in clinical trials, include diarrhoea, changes in blood counts such as eosinophilia and thrombocytosis, and elevations of liver enzymes. Uncommon effects may include injection site pain and headache. Adverse reactions are grouped by System-Organ-Class, which include the Gastrointestinal disorders, Blood and lymphatic system disorders, and Hepatobiliary disorders.

Serious Adverse Reactions

Regulatory sources explicitly document serious adverse reactions, which, though rare, are critical safety considerations. These include severe allergic reactions such as anaphylaxis and severe skin conditions like Stevens-Johnson syndrome. Also documented are haemolytic anaemia and Clostridium difficile-associated diarrhoea (CDAD), which can range to fatal colitis.

Population-Specific Safety Constraints

A major safety constraint is the absolute contraindication against the simultaneous administration of Ceftriaxone with intravenous calcium-containing solutions in all patients due to the risk of precipitation in the vascular system. This risk is particularly severe in neonates (infants le 28 days), where fatal cases involving ceftriaxone-calcium precipitation have been reported in the lungs and kidneys. Ceftriaxone is also contraindicated in hyperbilirubinemic neonates. Additionally, prolonged use is noted to carry the risk of superinfection by non-susceptible organisms. The formation of gallbladder precipitates (pseudolithiasis) is a documented hepatobiliary finding, particularly with higher doses in children.

Overdose and Emergency Response

The official regulatory documentation for Glen (Ceftriaxone) outlines the documented signs and required actions in the event of an overdose. Potential manifestations include general symptoms such as nausea, vomiting, and diarrhea. More serious presentations listed in official labeling involve reversible neurological effects, specifically including the potential for convulsions (seizures) and encephalopathy, alongside the occurrence of headache and oliguria (reduced urine output).

A major documented complication of high-dose exposure is the formation of Ceftriaxone-calcium precipitates. This can affect the hepatobiliary system, resulting in pseudolithiasis (gallbladder stones), or the renal system, where renal precipitates may contribute to acute renal failure. Due to the risk of such severe outcomes, the regulatory requirement is to seek immediate medical attention for any suspected overdose and to immediately discontinue the medicine.

No specific antidote for Ceftriaxone overdose is known. Therefore, official guidance confirms that management relies strictly upon symptomatic and supportive treatment under close clinical monitoring. Dialysis is generally not documented as an effective method for reducing drug concentration. Increased caution and monitoring are specifically noted for neonates, infants, and patients with pre-existing renal or hepatic impairment due to the heightened risk of precipitation complications.

Therapeutic Uses of Glen

What Glen Treats: Main Uses and Benefits

Glen is commonly used in situations involving certain distressing symptoms, applied across therapeutic domains where short-term symptomatic assistance is needed. This is relevant in contexts involving heightened systemic burden, often seen in conditions characterized by periods of heightened symptoms. Supportive management is often required for conditions characterized by periods of heightened symptoms and functional strain.


Therapeutic Symptom Support

Glen is commonly used to help with symptom clusters that may become intense or disruptive, such as those associated with acute or episodic changes. It is considered relevant for easing symptoms related to physical discomfort, systemic imbalance, and increased physiological activity. The medication is applied in addressing various presentations where symptoms interfere with daily functioning, including those linked to organ-specific functional stress.


Supportive Relief for Functional Strain

Relevant in clinical settings marked by heightened systemic burden, Glen is generally applied in scenarios where symptoms create noticeable physiological strain. It contributes to improved day-to-day comfort during periods of heightened symptoms and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Temporary Functional Strain


Eligibility and Restrictions for Use

Glen (Ceftriaxone) eligibility is strictly defined by regulatory documents, focusing on patient status, allergy, age, and coexisting physiological conditions. The official profile establishes clear rules on who is permitted to use the medicine and who is absolutely restricted.


Populations Who Must Not Use Glen (Contraindicated)

The medicine is absolutely contraindicated in patients with a known hypersensitivity to ceftriaxone, any excipients, or other cephalosporin-class antibacterials. Use is also formally prohibited in specific neonatal populations:

  • Premature neonates up to 41 weeks postmenstrual age.
  • Hyperbilirubinemic neonates.
  • Any neonate (≤ 28 days) requiring or expected to receive calcium-containing intravenous (IV) solutions.
  • Intravenous administration of the solution if it was reconstituted with a lidocaine-containing diluent.

Populations with Labeled Restrictions

Glen is generally approved for use in adults and pediatric patients (children ≥ 15 days of age). Use during pregnancy is permitted only if clearly needed, as adequate human safety studies are lacking. Caution is required for patients with a history of colitis or concurrent severe hepatic and renal impairment; in the latter case, the daily dosage should not exceed 2 grams.

What should I know about interactions with other medicines?

Glen (Ceftriaxone) interactions are strictly documented in regulatory information, focusing on required restrictions and potential pharmacodynamic outcomes.

Interaction scope

Category Description based on Regulatory Documents
Medicinal product categories with documented interactions: Intravenous calcium-containing solutions, Oral Anticoagulants, Bacteriostatic antibiotics, Aminoglycosides, Oral Hormonal Contraceptives.
Timing-based interaction rules (if applicable): Simultaneous intravenous administration of Glen and calcium-containing solutions is prohibited in all patients; flushing of the IV line between sequential administrations is required for patients over 28 days of age.
Population-specific interaction notes (if applicable): Co-administration with intravenous calcium-containing solutions is formally contraindicated in neonates (le 28 days old) due to the risk of fatal precipitation.

Resulting interaction structure

Official regulatory documents define interactions as follows:

  • Contraindicated Combination: Co-administration with intravenous calcium solutions is formally prohibited in neonates due to precipitation risk.
  • Exposure Modification: The use of Glen with Oral Anticoagulants (e.g., Warfarin) is documented to increase the official risk of bleeding complications.
  • Pharmacodynamic Interference: Regulatory sources note potential antagonistic effects when Ceftriaxone is combined with bacteriostatic agents like Chloramphenicol. Co-administration with Aminoglycosides is officially noted to potentially increase the risk of nephrotoxicity.
  • Efficacy Impact: Ceftriaxone may reduce the efficacy of oral hormonal contraceptives.
  • Physical Incompatibilities: Glen is physically incompatible with substances such as Vancomycin and Amsacrine and should not be mixed with them.

The overall interaction profile is structured by a core physical incompatibility with calcium solutions that governs strict administration timing and outright contraindication in neonates, alongside documented pharmacodynamic risks that necessitate caution with other select medicines to mitigate increased toxicity or altered therapeutic effects.

Mechanism of Action

Glen functions primarily as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABAA) receptor, a key molecular target mediating nerve inhibition in the central nervous system (CNS).

This interaction enhances the receptor's sensitivity to the neurotransmitter GABA, allowing more negatively charged chloride ions (Cl^-) to flow into the neuron. The resulting influx of chloride ions makes the cell membrane hyperpolarized, thereby suppressing neuronal signaling across major brain networks. This action fundamentally alters the balance between inhibitory (GABAergic) and excitatory (glutamatergic) signaling, shifting the overall neural network activity toward inhibition.

The widespread suppression of activity in regulatory regions, including the Reticular Activating System (RAS), directly results in the physiological change known as CNS depression. This mechanistic cascade translates into the observed systemic effects of loss of consciousness and amnesia. Additionally, the mechanism influences brainstem centers, leading to a predictable decrease in central respiratory drive and blood pressure (hypotension).

Dosage and Administration Information

How to Use Glen (Ceftriaxone): Administration Guidelines

The usage of Glen, which contains the active ingredient Ceftriaxone, follows specific protocols. This antibiotic is intended for parenteral administration only, meaning it must be delivered via injection or infusion to achieve systemic therapeutic effect.


Administration and Dosing

The medication is supplied as a sterile powder for solution that requires reconstitution with a sterile diluent immediately before use. Administration is typically performed through either a slow Intravenous (IV) injection over 2 to 4 minutes, an IV infusion over at least 30 minutes, or a deep Intramuscular (IM) injection.

The standardized adult dose usually ranges from 1 gram (g) to 2 g daily, administered once every 24 hours. The maximum daily dose for adults is strictly limited to 4 g. For certain severe infections, the daily dose may be divided and given every 12 hours.


Procedural Requirements and Duration

Instructions strictly prohibit the simultaneous mixing or co-administration of Ceftriaxone solutions with any intravenous solutions that contain calcium, due to the risk of precipitation. Dosing for older adults is generally not required to be modified, provided kidney and liver function are satisfactory. However, in cases of severe kidney impairment, the daily dose should not exceed 2 g.

The duration of treatment typically varies from 4 to 14 days, with administration generally continuing for a minimum of 48 to 72 hours after the patient's symptoms improve or evidence of bacterial eradication is confirmed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Glen (Ceftriaxone)


Evidence for Use in Central Nervous System Infections (e.g., Meningitis)

Research on Glen's use for infections of the central nervous system, such as bacterial meningitis, is based on extensive clinical evaluation. These studies primarily include Randomized Controlled Trials (RCTs) and systematic reviews exploring Glen's use compared to other established antibacterial agents. The main focus of these studies was to monitor outcomes such as microbiological clearance (eradication) from the cerebrospinal fluid, patient 30- and 90-day mortality rates, and subsequent patterns of neurological outcomes.

Studies conducted during periods of increased symptom activity reported measurements of this microbiological clearance and described patterns of clinical status measured during the course of active treatment. What remains uncertain is the need for continuous research, due to the global emergence of antimicrobial resistance. This requires ongoing investigation to explore patterns of microbiological response against current bacterial strains.


Evidence for Use in Lower Respiratory Tract Infections

The research exploring Glen's role in infections like community-acquired pneumonia includes RCTs that evaluated Glen against other injectable antibiotics. Researchers measured endpoints such as overall clinical outcome or failure rates, the frequency of re-hospitalization within 30 days, and observed 30-day all-cause mortality rates. Trial designs often focused on demonstrating that Glen was non-inferior when compared to older treatment regimens.

Robust clinical data on dosing and use when Glen is used alone (monotherapy) in the most critically ill patient populations is limited. The evidence provides context but not individual predictions, and long-term data tracking patient respiratory health and function beyond the 30-day post-treatment period are not fully established in the primary regulatory research.


What is Still Uncertain About Glen's Research

A primary ongoing uncertainty stems from the continuous evolution of antimicrobial resistance, which necessitates ongoing monitoring to explore treatment protocols against emerging bacterial strains. The evidence quality varies across studies, with a mix of high-quality RCTs for certain indications and reliance on smaller, observational studies for more complicated infections. Furthermore, long-term effects are not fully established, and there is limited information on the extended functional outcomes of patients treated with Glen.

Frequently Asked Questions (FAQ)

Common questions about Glen (FAQ)


Q: How quickly does Glen typically start working?

Official information, such as pharmacokinetic data, indicates the medicine reaches its highest concentration in the bloodstream within a few hours of administration (e.g., 2 to 3 hours after IM injection). However, regulatory documents do not provide a general timeline for when a patient should expect to see specific signs of clinical improvement from the infection.


Q: Does Glen need to be taken long-term?

No, official documentation describes Glen as a short-course treatment for infections. The typical duration of therapy is defined as four to fourteen days. Official product documentation states that administration generally continues for a minimum of 48 to 72 hours after symptoms improve or infection is confirmed clear.


Q: Can Glen affect the results of any common lab tests?

Yes, regulatory documents list changes in certain lab results as known adverse reactions. These changes may include temporary shifts in blood counts, such as eosinophilia and thrombocytosis, and elevations of liver enzymes. These changes are documented as known adverse reactions.


Q: Are there different strengths or dosages of Glen available?

Yes, Glen (Ceftriaxone) is available in several different package strengths. Official regulatory information confirms that it is supplied as a sterile powder for solution in single-use vials, with common sizes including 250 mg, 500 mg, 1 g, and 2 g.


Q: What kind of monitoring or blood tests are needed while taking Glen?

Regulatory warnings note the risk of changes in blood cell counts and liver enzyme levels. Regulatory documents highlight the importance of assessing kidney and liver function, particularly for patients with severe impairment. The need for specific monitoring is an individualized clinical decision.


Q: Is it normal to have mild stomach upset when starting Glen?

Gastrointestinal side effects are documented in official safety information. Diarrhoea or loose stools are classified as one of the most common adverse reactions. Less common effects that could cause general upset include nausea and vomiting.


Q: If I feel better, can I stop taking Glen on my own?

The official instructions specify that administration should continue for at least 48 to 72 hours even after symptoms have improved. The continuance of therapy beyond symptom improvement, as described in regulatory documentation, is related to confirming the eradication of the bacterial infection.


Q: What kind of studies were done to get Glen approved?

Regulatory approval was based on extensive clinical evaluation and research. This included Randomized Controlled Trials (RCTs) designed to measure outcomes such as microbiological clearance (the elimination of bacteria) and to demonstrate that Glen was comparable to other existing treatments.


Q: What are the success rates mentioned in research about Glen?

Research published in regulatory documents focuses on measured clinical endpoints rather than a single 'success rate.' Key metrics examined in studies include rates of microbiological clearance (eradication), patient mortality rates, and clinical outcome or failure rates.


Q: Can Glen be split or crushed before taking it?

Glen is not supplied as an oral pill or capsule. It is supplied as a sterile powder for solution that is mixed with liquid and administered exclusively via IV or IM injection or infusion. Due to its parenteral (injection) route of administration, typical instructions regarding splitting or crushing tablets do not apply to this sterile powder formulation.


Q: Are there any common foods or drinks that interact with Glen?

Official regulatory documents list specific interactions with certain other medicines and intravenous solutions containing calcium. However, the documentation does not list any common foods or drinks (such as grapefruit, dairy, or specific dietary items) as documented interaction risks with the active ingredient Ceftriaxone.


Q: Does Glen cause weight gain or weight loss?

Official lists of side effects generally do not include weight gain as a commonly reported adverse reaction. Some regulatory lists mention unusual weight loss as a rare side effect of unknown frequency in certain populations.


Q: Can Glen affect my mood or mental state?

Official regulatory sources note documented effects on the nervous system, including headache and dizziness. Rare events such as seizures or convulsions are also documented as potential nervous system adverse reactions.


Q: Is it safe to drive while taking Glen?

The potential for side effects such as dizziness and headache is noted in official documents. Due to the potential for such effects, caution is suggested regarding activities that require full concentration, such as driving or operating machinery, consistent with product labeling.


Q: Why do some people say they feel tired after taking Glen?

Regulatory documents report unusual tiredness or weakness (sometimes described as malaise) among the possible documented side effects of the medication.


Q: Can I drink alcohol while I am taking Glen?

Official regulatory documents list specific drug-drug interactions and solution incompatibilities. Alcohol is not listed as a documented interaction risk with the active ingredient Ceftriaxone in these official sources.


Q: What is the risk of dependence or withdrawal with Glen?

Glen is a cephalosporin antibiotic used to treat bacterial infections. It is not classified as a controlled substance by the DEA, and its mechanism of action is not associated with the central nervous system pathways that lead to dependence.


Q: Is Glen a controlled substance?

Glen (Ceftriaxone) is a prescription-only (Rx-Only) medicine and is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent international regulatory bodies.


Q: Is Glen available as a generic medicine?

Yes, regulatory records from the FDA confirm that generic Ceftriaxone is widely available and approved through Abbreviated New Drug Applications. This indicates that non-brand versions of the medicine have met regulatory standards.


Q: How long does Glen stay in your system after stopping treatment?

The length of time a medicine remains in the body is determined by its elimination half-life. Regulatory documents state that the average elimination half-life of Glen (Ceftriaxone) in healthy adults is approximately 8 hours.


Q: Does taking Glen at night or in the morning make a difference?

Official dosing instructions typically state that the dose is administered once every 24 hours to ensure constant levels in the body. The regulatory information does not specify a clinical difference based on whether the drug is given in the morning or at night.


Q: Can Glen interact with herbal supplements?

Official regulatory interaction sections list specific drug and solution interactions. However, the regulatory interaction sections do not document an interaction with herbal supplements.


Q: Is Glen commonly used in combination with other medicines?

The regulatory documents list potential risks that arise when Glen is co-administered with certain other medicines, such as Aminoglycosides and bacteriostatic antibiotics. The fact that these risks are described implies that co-administration is a recognized practice in certain clinical cases.


Q: Are there any documented long-term side effects associated with Glen?

Official documents note that clinical long-term data tracking patient health beyond the 30-day post-treatment period are not fully established. However, risks noted with prolonged use include the formation of gallbladder precipitates (pseudolithiasis) and the potential for superinfection by non-susceptible organisms.


Q: Can Glen interact with over-the-counter pain relievers like ibuprofen?

Official regulatory interaction sections list specific drug categories that have known risks, such as anticoagulants and calcium solutions. However, the documents do not document an interaction with common over-the-counter pain relievers like ibuprofen.

How should Glen be stored and disposed of?

Storage and Disposal Requirements for Glen (Ceftriaxone)

Official labeling defines strict requirements for storing and disposing of this medicine to maintain its potency.

Storage/Disposal Scope Official Regulatory Requirement
Powder Storage Temperature Store the unopened sterile powder at controlled room temperature (e.g., 20 C to 25 C) and protect from light (keep in original carton).
Stability After Reconstitution The solution has a limited stability period (e.g., typically 24 hours at room temperature or up to 10 days refrigerated) and must not be frozen.
Handling Constraints The medicine must be kept out of the sight and reach of children at all times.
Disposal Instructions Unused or expired Ceftriaxone must be discarded according to local regulations, preferably by using a drug take-back location. Do not dispose of the antibiotic via wastewater or household trash unless officially instructed.

Regulatory documents mandate that the unopened powder must be stored under specific environmental controls to preserve its quality. This is contrasted with the mixed solution, which requires adherence to a brief, strictly defined shelf-life under refrigeration or immediate use. Final disposal must follow official local protocols to safely manage the pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glen found in:

A-Z Index: